EDITAS MEDICINE, INC. Contract with Customer, Performance Obligation Satisfied in Previous Period
EDITAS MEDICINE, INC. (EDIT) reported Contract with Customer, Performance Obligation Satisfied in Previous Period of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Notes
us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod · last filed 2026-03-09
- EDITAS MEDICINE, INC. contract with customer, performance obligation satisfied in previous period for the quarter ending 2025-06-30 was $0.00.
- EDITAS MEDICINE, INC. contract with customer, performance obligation satisfied in previous period for the quarter ending 2024-06-30 was $0.00.
- EDITAS MEDICINE, INC. contract with customer, performance obligation satisfied in previous period for the quarter ending 2020-12-31 was $0.00, a 100.00% decline year-over-year.
- EDITAS MEDICINE, INC. contract with customer, performance obligation satisfied in previous period for the quarter ending 2020-09-30 was $0.00, a 100.00% decline year-over-year.
- EDITAS MEDICINE, INC. contract with customer, performance obligation satisfied in previous period for fiscal 2025 was $0.00.
- EDITAS MEDICINE, INC. contract with customer, performance obligation satisfied in previous period for fiscal 2024 was $0.00.
- EDITAS MEDICINE, INC. contract with customer, performance obligation satisfied in previous period for fiscal 2023 was $0.00.
- EDITAS MEDICINE, INC. contract with customer, performance obligation satisfied in previous period for fiscal 2020 was $60.00K, a 97.56% decline from fiscal 2019.
| Period end | Contract with Customer, Performance Obligation Satisfied in Previous Period 3 month | Contract with Customer, Performance Obligation Satisfied in Previous Period 6 month | Contract with Customer, Performance Obligation Satisfied in Previous Period 9 month | Contract with Customer, Performance Obligation Satisfied in Previous Period 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-09 | |||
| 2025-06-30 | $0.00 10-Q · filed 2025-08-12 | $0.00 10-Q · filed 2025-08-12 | ||
| 2024-12-31 | $0.00 10-K · filed 2026-03-09 | |||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-12 | $0.00 10-Q · filed 2025-08-12 | ||
| 2023-12-31 | $0.00 10-K · filed 2025-03-05 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $0.00 derived: sum of 2 quarters · filed 2021-02-26 | $0.00 derived: sum of 3 quarters · filed 2021-02-26 | $60.00K 10-K · filed 2021-02-26 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $0.00 derived: sum of 2 quarters · filed 2020-11-06 | $60.00K 10-Q · filed 2020-11-06 | $1.32M derived: sum of 4 quarters · filed 2020-11-06 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $60.00K 10-Q · filed 2020-08-07 | $1.32M derived: sum of 3 quarters · filed 2020-08-07 | $2.52M derived: sum of 4 quarters · filed 2020-08-07 |
| 2020-03-31 | $60.00K 10-Q · filed 2020-05-08 | $1.32M derived: sum of 2 quarters · filed 2020-05-08 | $2.52M derived: sum of 3 quarters · filed 2020-05-08 | |
| 2019-12-31 | $1.26M 10-K · filed 2020-02-26 | $2.46M derived: sum of 2 quarters · filed 2020-02-26 | $2.46M 10-K · filed 2020-02-26 | |
| 2019-09-30 | $1.19M 10-Q · filed 2019-11-12 | $1.19M 10-Q · filed 2019-11-12 | ||
| 2018-12-31 | $4.64M 10-K · filed 2019-03-01 | $3.39M derived: sum of 2 quarters · filed 2019-03-01 | $5.96M derived: sum of 3 quarters · filed 2019-03-01 | $5.96M 10-K · filed 2019-03-01 |
| 2018-09-30 | -$1.25M 10-Q · filed 2018-11-08 | $1.31M derived: sum of 2 quarters · filed 2018-11-08 | $1.31M 10-Q · filed 2018-11-08 | |
| 2018-06-30 | $2.57M 10-Q · filed 2018-08-07 | $2.57M 10-Q · filed 2018-08-07 | ||
| 2018-03-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |